文章：

恩科拉非尼与比尼美替尼治疗转移性黑色素瘤患者的真实世界心脏毒性研究

Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib

原文发布日期：23 August 2024

DOI: 10.3390/cancers16172945

类型: Article

开放获取: 是

英文摘要：

Modern therapies targeting the BRAF gene mutation in advanced melanoma have significantly improved patient outcomes but pose cardiovascular risks. This retrospective study in Eastern Denmark (2019–2022) assessed 108 melanoma patients treated with encorafenib and binimetinib. Patients were monitored for heart function using multigated acquisition (MUGA) scans. The study defined major cardiotoxicity as a decline in left ventricular ejection fraction (LVEF) by more than 10 percentage points to below 50%, and minor cardiotoxicity as a decrease in LVEF by more than 15 points but remaining above 50%. Results showed that 19 patients (18%) developed minor cardiotoxicity and were asymptomatic, while 7 (6%) experienced major cardiotoxicity, with two requiring intervention. Notably, no significant declines in LVEF were observed after six months of treatment. The study concluded that significant cardiotoxicity occurred in 6% of cases, mostly asymptomatic and reversible, and suggests that monitoring LVEF could potentially be reduced after 6–9 months if no early signs of cardiotoxicity are detected. This provides valuable insights into the cardiac safety of these treatments in real-world settings.

摘要翻译： 

针对晚期黑色素瘤BRAF基因突变的现代疗法显著改善了患者预后，但存在心血管风险。这项在丹麦东部地区（2019-2022年）开展的回顾性研究评估了108例接受恩考芬尼联合比美替尼治疗的黑色素瘤患者。通过多门控采集扫描监测患者心功能，研究将主要心脏毒性定义为左心室射血分数下降超过10个百分点至50%以下，次要心脏毒性定义为LVEF下降超过15个百分点但仍高于50%。结果显示，19例患者（18%）出现无症状的次要心脏毒性，7例（6%）发生主要心脏毒性，其中两例需要临床干预。值得注意的是，治疗六个月后未观察到LVEF的显著下降。研究结论表明，6%的病例出现显著心脏毒性，多数呈无症状且可逆性，并提示若早期未检测到心脏毒性迹象，6-9个月后或可减少LVEF监测频率。这为真实世界中此类治疗的心脏安全性评估提供了重要参考。

原文链接：

Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib